A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem DTwP-HepB-Hib) in Uniject With Quinvaxem Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age

Trial Profile

A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem DTwP-HepB-Hib) in Uniject With Quinvaxem Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2016

At a glance

  • Drugs Hib-DTP-hepatitis B vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Crucell
  • Most Recent Events

    • 12 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 05 Sep 2013 Planned end date changed from 1 Sep 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top